within Pharmacolibrary.Drugs.C_CardiovascularSystem.C10A_LipidModifyingAgentsPlain.C10AX08_Policosanol;
model Policosanol 
   extends Pharmacolibrary.Drugs.ATC.C.C10AX08;

  annotation(Documentation(
    info ="<html><body><p>Policosanol is a mixture of long-chain primary aliphatic alcohols derived from plant waxes, commonly including octacosanol as the main component. It has been marketed as a lipid-lowering agent for treatment of hypercholesterolemia and cardiovascular risk management, but its efficacy and regulatory approval is controversial and not approved by major agencies such as FDA or EMA.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic models with quantifiable parameters are available for policosanol. Available data are limited to general statements about absorption and metabolism after oral administration in healthy adults.</p><h4>References</h4><ol><li><p>Abdul, MI, et al., &amp; McLachlan, AJ (2010). Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects. <i>British journal of clinical pharmacology</i> 69(5) 508–515. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.2010.03620.x&quot;>10.1111/j.1365-2125.2010.03620.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20573086/&quot;>https://pubmed.ncbi.nlm.nih.gov/20573086</a></p></li><li><p>Noa, M, et al., &amp; González, J (2004). Policosanol prevents bone loss in ovariectomized rats. <i>Drugs under experimental and clinical research</i> 30(3) 117–123. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15366788/&quot;>https://pubmed.ncbi.nlm.nih.gov/15366788</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Policosanol;
